


**BEST AVAILABLE COPY**



C3H/HeN  
UV2237m fibrosarcoma s.c.  
 $1 \times 10^6$  H5 cells/100 $\mu\text{l}$  saline

**FIG. 1**

BEST AVAILABLE COPY




FIG. 2

BEST AVAILABLE COPY






FIG. 3

BEST AVAILABLE COPY




C3H/HeN  
UV2237m fibrosarcoma s.c.  
H5IFN- $\beta$  lysate in 100 $\mu\text{l}$  saline

FIG. 4




C3H/HeN  
UV2237m fibrosarcoma s.c.  
 $2 \times 10^6$  H5 cell lysate/100 $\mu\text{l}$  saline

FIG. 5




BALB/C Nude  
UV2237m fibrosarcoma s.c.  
H5IFN- $\beta$  cell lysate/100 $\mu\text{l}$  saline

**FIG. 6**



**FIG. 7**



C3H/HeN  
UV2237m fibrosarcoma s.c.  
H5IFN- $\beta$  cell lysate/100 $\mu\text{l}$  saline

FIG. 8

BEST AVAILABLE COPY




FIG. 9

BEST AVAILABLE COPY

UV2237m CTR      H5mIFN $\beta$  alone      H5mIFN $\beta$ +IgG




FIG. 10

BEST AVAILABLE COPY




FIG. 11




FIG. 12

Treatment of Subcutaneous Tumors			Lung Metastasis Median (Range)	
Tumors	Treatment	Results	UV2237m	K1735
UV2237m	Saline	Progression	44(8-79)	>200(140->200)
UV2237m	H5IFNb	Regression	0(All)*	>200(5->200)
K1735	Saline	Progression	120(74-178)	92(44-152)
K1735	H5IFNb	Regression	121(14-131)	0(All)*

\*P<0.001, N=5, one of two representative experiments is shown.

UV2237m or K1735m2 cells were inoculated s.c. into C3H/HeN mice, when tumors were 4 mm in diameter, the mice were injected i.v. with either UV2237m or K1735m2 cells, 2 days later, the s.c. tumors were injected with saline or lyophilized H5IFNb( $2 \times 10^6$  cells-equivalent) (one injection for UV2237, 2 injections at 1wk interval for K1735m2). The diameter of s.c. tumors was determined every 5 days. The mice were killed and the number of lung metastases was counted 28 days after i.v. injection of the tumor cells.

**Induction of specific tumor immunity in C3H mice cured of UV2237m or K1735m2 primary subcutaneous tumors**

Group	s.c. Challenge		i.v. Challenge			
			UV2237m		K1735m2	
	Tumor Size (mm)		Lung Met.	Lung Weight	Lung Met.	Lung Weight
UV2237-cured	0*	9.2±5.3	0(0-0)*	242 ±31	191(107->200)	770 ±306
K1735-cured	6.0±4.3	0*	140(84->200)	847 ±230	0(0-0)*	228 ±22
Control	12.6 ±1.3	15.3 ±3.0	167(93->200)	898 ±227	>200(all>200)	1079 ±110

\*:P<0.001, N=10

Established s.c. UV2237m or K1735m2 tumors in C3H/HeN mice were cured by intratumoral injections of lyophilized H5IFN $\beta$  (one injection for UV2237m, two injections at 1wk interval for K1735m2). 2 months later after disappearance of s.c. tumors, the cured mice were challenged either s.c. or i.v. with either UV2237m or K1735m2 cells. s.c. tumor sizes were measured 2 weeks later after inoculation. The i.v. challenged mice were killed 4 weeks later, the lungs were weighed and fixed in Bouin's solution and metastatic nodules were counted under a dissecting microscope.

**FIG. 14**




FIG. 15




FIG. 16




FIG. 17

FIGURE 18




FIG. 18





FIG. 19

FIG. 20






FIG. 21






FIG. 22



\*:  $P < 0.05$ ,  $N=5$

**FIG. 23**



\*: Tumor incidence  
 a: P>0.05 compared with saline group  
 b: P<0.01 compared with saline group

**FIG. 24**